Parenteral Clomipramine Showed No Clear Advantage Over Oral Clomipramine

TL;DR: A 2026 systematic review and meta-analysis in Acta Neuropsychiatrica found no clear evidence that parenteral clomipramine is better than oral clomipramine for depression or obsessive-compulsive disorder, with low or very low certainty across the main randomized-trial evidence.

Source: Acta Neuropsychiatrica (2026) | Ioannou et al.

Parenteral clomipramine means clomipramine given by injection or infusion rather than by mouth. In practice, that usually means intravenous or intramuscular administration.

The rationale sounds plausible: more predictable absorption, faster steady-state levels, and fewer immediate adherence problems. This review asked whether randomized trials actually show better symptom outcomes.

Parenteral Clomipramine Has Been Used Despite Thin Trial Evidence

Clomipramine is a tricyclic antidepressant used for depression and obsessive-compulsive disorder (OCD). The parenteral route has remained in use in some inpatient settings, especially when clinicians want rapid symptom relief or cannot rely on oral dosing.

Researchers framed the question around whether parenteral clomipramine improved depressive or OCD symptoms within 2 weeks, compared with oral clomipramine, other treatments, or placebo.

• Depression group: Eleven RCTs included 317 patients with depression.
• OCD group: Three RCTs included 101 patients with OCD.
• Main measurement: Depression conclusions relied mainly on Hamilton Depression Rating Scale (HDRS) change, while OCD conclusions relied on Yale-Brown Obsessive Compulsive Scale (Y-BOCS) change.

GRADE certainty was central to the review. GRADE is a framework for rating how confident readers should be that an effect estimate is close to the true effect.

Depression Trials Did Not Show Clear Superiority Over Oral Clomipramine

For the main depression question, the evidence came from 5 double-blind RCTs without high risk of bias. Together, they included 170 patients comparing parenteral and oral clomipramine within 2 weeks.

The pooled HDRS change at 2 weeks was -1.27 points favoring parenteral administration, but the 95% confidence interval ranged from -3.09 to 0.54. Because the interval crossed zero, the meta-analysis did not show a clear advantage.

The review also looked at longer-term depression symptoms beyond 2 weeks. The pooled estimate was -1.06 HDRS points, with a wide interval from -4.70 to 2.58 and higher heterogeneity.

OCD Findings Were Too Heterogeneous for a Firm Answer

For OCD, the strongest direct evidence was smaller and more inconsistent. Two lower-bias RCTs with 47 patients compared parenteral with oral clomipramine for OCD symptoms within 2 weeks.

Researchers did not pool those trials because the study designs and patient groups were too different. One placebo-controlled OCD trial in patients poorly responsive to oral clomipramine included 54 patients and reported a Y-BOCS mean difference of -2.5 points, with a 95% confidence interval from -5.6 to 0.6.

1. Oral comparator: Existing OCD trials did not establish parenteral superiority over oral clomipramine.
2. Placebo comparator: The placebo comparison did not show a statistically clear symptom advantage.
3. Evidence certainty: The review rated the OCD evidence as very low certainty because of small samples, inconsistency, and imprecision.

That does not prove parenteral clomipramine never helps an individual patient. It means the randomized evidence is not strong enough to support the route as generally superior.

Missing Outcomes Limit the Inpatient Interpretation

The review’s biggest practical limitation was not just small sample size. Many outcomes that matter in severe inpatient care were absent from the randomized evidence.

• Safety-critical outcomes: No RCT reported suicide attempts, all-cause mortality, or suicidal ideation.
• Function and recovery: No RCT reported global functioning or health-related quality of life.
• Hospital operations: No RCT reported hospital length of stay, even though parenteral use is often discussed in inpatient settings.

Infusion-related adverse events were reported in some trials, including thrombophlebitis and cardiac arrhythmia, but the evidence base was too small and heterogeneous for a clean pooled safety estimate.

Oral Treatment Remains the Default Reading

The review’s practical conclusion was restrained: parenteral clomipramine may not be favorable compared with oral administration, and a short-term depression benefit cannot be fully excluded because the estimates were imprecise.

That is different from saying oral clomipramine is ineffective. The review evaluated the route of administration, not whether clomipramine itself can work for depression or OCD.

Route matters because infusion requires staff time, monitoring, venous access, and management of administration reactions. A treatment route should earn that added burden with evidence that patients do better in ways that matter.

• Best-supported use: Oral clomipramine remains the simpler route when patients can take and absorb medication reliably.
• Possible exception: Parenteral treatment may remain a niche option when oral administration is not feasible or when an inpatient team accepts the uncertainty.
• Research need: New trials would need relevant comparators such as ECT or ketamine and patient-centered outcomes beyond symptom scores.

For now, the evidence does not support routine use of parenteral clomipramine as a superior depression or OCD strategy.